Table 5.

Future challenges of research on ICS therapy in bronchiectasis

To irrefutably establish the efficacy and safety of ICSs in bronchiectasis

To verify the consequences of discontinuing ICSs in bronchiectasis

To analyze COPD/bronchiectasis and asthma/bronchiectasis overlaps

To assess the possible benefits of combined therapy with macrolides and ICSs in severe patients

To identify the bronchiectasis phenotypes most susceptible to ICS treatment

To determine which is the best ICS, if any, and its best posology (in monotherapy or in combination with bronchodilators) in the treatment of bronchiectasis

COPD chronic obstructive pulmonary disease, ICS inhaled corticosteroids